

DAFTAR PUSTAKA

1. Hoogeveen EK. The Epidemiology of Diabetic Kidney Disease. *Kidney and Dialysis*. 2022;2(3):433–42.
2. Forouhi NG, Wareham NJ. Epidemiology of diabetes. *Medicine*. 2022;50(10):638–43.
3. Chou CY, Hsu DY, Chou CH. Predicting the Onset of Diabetes with Machine Learning Methods. *J Pers Med*. 2023 Feb 24;13(3):406.
4. Kivimäki M, Kuosma E, Ferrie JE, Luukkonen R, Nyberg ST, Alfredsson L, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. *Lancet Public Health*. 2017;2(6):e277–85.
5. Monteiro R, Azevedo I. Chronic Inflammation in Obesity and the Metabolic Syndrome. *Mediators Inflamm* [Internet]. 2010;2010:1–10. Available from: <http://dx.doi.org/10.1155/2010/289645>
6. Lee H, Jose PA. Coordinated Contribution of NADPH Oxidase- and Mitochondria-Derived Reactive Oxygen Species in Metabolic Syndrome and Its Implication in Renal Dysfunction. *Front Pharmacol*. 2021;12.
7. Flood D, Seiglie JA, Dunn M, Tschida S, Theilmann M, Marcus ME, et al. The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults. *Lancet Healthy Longev*. 2021;2(6):e340–51.
8. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract*. 2022;183:109119.
9. Nurwadjedi, Hartini S, Rosalina L. Developing one map of national marine resources of Indonesia. *IOP Conf Ser Earth Environ Sci*. 2018;162:012028.
10. Widayanti AW, Green JA, Heydon S, Norris P. Health-Seeking Behavior of People in Indonesia: A Narrative Review. *J Epidemiol Glob Health*. 2020;10(1):6.
11. Gomez-Zavaglia A, Prieto Lage MA, Jimenez-Lopez C, Mejuto JC, Simal-Gandara J. The Potential of Seaweeds as a Source of Functional Ingredients of Prebiotic and Antioxidant Value. *Antioxidants*. 2019;8(9):406.
12. Sanjeewa KKA, Lee W, Jeon YJ. Nutrients and bioactive potentials of edible green and red seaweed in Korea. *Fish Aquatic Sci*. 2018;21(1).
13. Nurkolis F, Taslim NA, Qhabibi FR, Kang S, Moon M, Choi J, et al. Ulvophyte Green Algae *Caulerpa lentillifera*: Metabolites Profile and Antioxidant, Anticancer, Anti-Obesity, and In Vitro Cytotoxicity Properties. *Molecules*. 2023;28(3):1365.

14. Dissanayake IH, Bandaranayake U, Keerthirathna LR, Manawadu Chamalika, Silva RM, Mohamed B, et al. Integration of in vitro and in-silico analysis of *Caulerpa racemosa* against antioxidant, antidiabetic, and anticancer activities. *Sci Rep*. 2022;12(1).
15. Permatasari HK, Nurkolis F, Augusta PS, Mayulu N, Kuswari M, Taslim NA, et al. Kombucha tea from seagrapes (*Caulerpa racemosa*) potential as a functional anti-ageing food: in vitro and in vivo study. *Heliyon*. 2021;7(9):e07944.
16. Permatasari HK, Firani NK, Prijadi B, Irnandi DF, Riawan W, Yusuf M, et al. Kombucha drink enriched with sea grapes (*Caulerpa racemosa*) as potential functional beverage to contrast obesity: An in vivo and in vitro approach. *Clin Nutr ESPEN*. 2022;49:232–40.
17. Permatasari HK, Nurkolis F, Hardinsyah H, Taslim NA, Sabrina N, Ibrahim FM, et al. Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of *Caulerpa racemosa* as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor- γ Coactivator 1- α Levels. *Front Nutr*. 2022;9.
18. Jain A, Sirisha VL. Algal Carotenoids. In: Encyclopedia of Marine Biotechnology. Wiley; 2020. p. 33–64.
19. Mohibbullah Md, Haque MdN, Sohag AAM, Hossain MdT, Zahan MdS, Uddin MdJ, et al. A Systematic Review on Marine Algae-Derived Fucoxanthin: An Update of Pharmacological Insights. *Mar Drugs*. 2022;20(5):279.
20. Miyashita K, Nishikawa S, Beppu F, Tsukui T, Abe M, Hosokawa M. The allenic carotenoid fucoxanthin, a novel marine nutraceutical from brown seaweeds. *J Sci Food Agric*. 2011;91(7):1166–74.
21. Mikami K, Hosokawa M. Biosynthetic Pathway and Health Benefits of Fucoxanthin, an Algae-Specific Xanthophyll in Brown Seaweeds. *Int J Mol Sci*. 2013;14(7):13763–81.
22. Yalçın S, Karakaş Ö, Okudan EŞ, Başkan KS, Çekiç SD, Apak R. HPLC Detection and Antioxidant Capacity Determination of Brown, Red and Green Algal Pigments in Seaweed Extracts. *J Chromatogr Sci*. 2020;59(4):325–37.
23. Kurniawan R, Nurkolis F, Taslim NA, Subali D, Surya R, Gunawan W Ben, et al. Carotenoids Composition of Green Algae *Caulerpa racemosa* and Their Antidiabetic, Anti-Obesity, Antioxidant, and Anti-Inflammatory Properties. *Molecules*. 2023;28(7):3267.
24. Souza CRM, Bezerra WP, Souto JT. Marine Alkaloids with Anti-Inflammatory Activity: Current Knowledge and Future Perspectives. *Mar Drugs*. 2020 Mar 2;18(3):147.
25. Piazzì L, Balata D, Bulleri F, Gennaro P, Ceccherelli G. The invasion of *Caulerpa cylindracea* in the Mediterranean: the known, the unknown and the knowable. *Mar Biol*. 2016;163(7).
26. Syakilla N, George R, Chye FY, Pindi W, Mantihal S, Wahab NA, et al. A Review on Nutrients, Phytochemicals, and Health Benefits of Green Seaweed, *Caulerpa lentillifera*. *Foods*. 2022;11(18):2832.

27. Hapsari Y, Rahmawati SI, Izzati F, Septiana E, Bustanussalam, Rachman F, et al. *Caulerpa lentillifera* as a potential nutraceutical resource. In 2023. p. 020006.
28. Zheng H, Zhou W, Shi Y, Yang S, Tang X, Xiong Y, et al. Active Components and Skin Care Mechanism of Sea Grape (*Caulerpa lentillifera*) Extract. *J Biobased Mater Bioenergy*. 2024;18(5):868–77.
29. Raniello R, Lorenti M, Brunet C, Buia MC. Photoacclimation of the invasive alga *Caulerpa racemosa* var. *cylindracea* to depth and daylight patterns and a putative new role for siphonaxanthin. *Marine Ecology*. 2006;27(1):20–30.
30. Hu CC, Lin JT, Lu FJ, Chou FP, Yang DJ. Determination of carotenoids in *Dunaliella salina* cultivated in Taiwan and antioxidant capacity of the algal carotenoid extract. *Food Chem*. 2008 Jul;109(2):439–46.
31. Agirbasli Z, Cavas L. In silico evaluation of bioactive peptides from the green algae *Caulerpa*. *J Appl Phycol*. 2017;29(3):1635–46.
32. Echave J, Otero P, Garcia-Oliveira P, Munekata PES, Pateiro M, Lorenzo JM, et al. Seaweed-Derived Proteins and Peptides: Promising Marine Bioactives. *Antioxidants*. 2022;11(1):176.
33. Kurniawan R, Taslim NA, Hardinsyah H, Syauki AY, Idris I, Aman AM, et al. Pharmacoinformatics and cellular studies of algal peptides as functional molecules to modulate type-2 diabetes markers. *Future Foods*. 2024 Jun;9:100354.
34. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic syndrome and cardiovascular disease. *Annals of Clinical Biochemistry: International Journal of Laboratory Medicine*. 2007;44(3):232–63.
35. Kaur J. A Comprehensive Review on Metabolic Syndrome. *Cardiol Res Pract*. 2014;2014:1–21.
36. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nat Genet*. 2012;44(9):991–1005.
37. Lam TP, Tran NVN, Pham LHD, Lai NVT, Dang BTN, Truong NLN, et al. Flavonoids as dual-target inhibitors against α -glucosidase and α -amylase: a systematic review of in vitro studies. *Nat Prod Bioprospect*. 2024;14(1).
38. Sun C, Zhao C, Guven EC, Paoli P, Simal-Gandara J, Ramkumar KM, et al. Dietary polyphenols as antidiabetic agents: Advances and opportunities. *Food Front*. 2020;1(1):18–44.
39. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans. *Cell Metab*. 2011;14(5):612–22.
40. Sahebkar A, Serban MC, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. *J Funct Foods*. 2015;18:898–909.

41. Bhatnagar A, Mishra A. α -Glucosidase Inhibitors for Diabetes/Blood Sugar Regulation. In: Natural Products as Enzyme Inhibitors. Singapore: Springer Nature Singapore; 2022. p. 269–83.
42. Li F, Luo T, Hou J, Fei T, Zhang J, Wang L. Natural α -glucosidase and α -amylase inhibitors from raspberry (*Rubus corchorifolius* L.) leaf-tea: Screening, identification and molecular docking analysis. *LWT*. 2023 May;181:114763.
43. Kalinovskii AP, Sintsova O V., Gladkikh IN, Leychenko E V. Natural Inhibitors of Mammalian α -Amylases as Promising Drugs for the Treatment of Metabolic Diseases. *Int J Mol Sci*. 2023 Nov 20;24(22):16514.
44. Lass A, Zimmermann R, Oberer M, Zechner R. Lipolysis – A highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. *Prog Lipid Res*. 2011;50(1):14–27.
45. Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomedicine & Pharmacotherapy*. 2020;128:110314.
46. Choi SS, Park J, Choi JH. Revisiting PPAR γ as a target for the treatment of metabolic disorders. *BMB Rep*. 2014 Nov 30;47(11):599–608.
47. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPAR γ signaling and metabolism: the good, the bad and the future. *Nat Med*. 2013;19(5):557–66.
48. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2012 Dec 4;8(12):728–42.
49. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. *Diabetes Obes Metab*. 2018;20(S1):5–21.
50. Thomas MC, Coughlan MT, Cooper ME. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. *Cell Metab*. 2023 Feb;35(2):253–73.
51. Wu H, Deng X, Shi Y, Su Y, Wei J, Duan H. PGC-1 α , glucose metabolism and type 2 diabetes mellitus. *Journal of Endocrinology*. 2016 Jun;229(3):R99–115.
52. Miao R, Fang X, Wei J, Wu H, Wang X, Tian J. Akt: A Potential Drug Target for Metabolic Syndrome. *Front Physiol*. 2022;13.
53. Myers MG, Cowley MA, Münzberg H. Mechanisms of Leptin Action and Leptin Resistance. *Annu Rev Physiol*. 2008 Mar 1;70(1):537–56.
54. Paz-Filho G, Mastronardi C, Wong ML, Licinio J. Leptin therapy, insulin sensitivity, and glucose homeostasis. *Indian J Endocrinol Metab*. 2012;16(9):549.
55. Abiola JO, Oluyemi AA, Idowu OT, Oyinloye OM, Ubah CS, Owolabi OV, et al. Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus. *Pharmaceuticals*. 2024 Jun 5;17(6):736.

56. Suganami T, Nishida J, Ogawa Y. A Paracrine Loop Between Adipocytes and Macrophages Aggravates Inflammatory Changes. *Arterioscler Thromb Vasc Biol.* 2005;25(10):2062–8.
57. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. *Nature.* 2017;542(7640):177–85.
58. Akash MSH, Rehman K, Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. *J Cell Biochem.* 2018 Jan 22;119(1):105–10.
59. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol.* 2006;6(10):772–83.
60. Li H, Meng Y, He S, Tan X, Zhang Y, Zhang X, et al. Macrophages, Chronic Inflammation, and Insulin Resistance. *Cells.* 2022 Sep 26;11(19):3001.
61. Kang MC, Cha SH, Wijesinghe WJ, Kang SM, Lee SH, Kim EA, et al. Protective effect of marine algae phlorotannins against AAPH-induced oxidative stress in zebrafish embryo. *Food Chem.* 2013;138(2–3):950–5.
62. Kim KN, Heo SJ, Kang SM, Ahn G, Jeon YJ. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. *Toxicology in Vitro.* 2010;24(6):1648–54.
63. Maeda H, Kanno S, Kodate M, Hosokawa M, Miyashita K. Fucoxanthinol, Metabolite of Fucoxanthin, Improves Obesity-Induced Inflammation in Adipocyte Cells. *Mar Drugs.* 2015;13(8):4799–813.
64. Cohen JC, Horton JD, Hobbs HH. Human Fatty Liver Disease: Old Questions and New Insights. *Science.* 2011;332(6037):1519–23.
65. Ha AW, Kim WK. The effect of fucoxanthin rich powder on the lipid metabolism in rats with a high fat diet. *Nutr Res Pract.* 2013;7(4):287.
66. Ghasemi F, Navab F, Rouhani MH, Amini P, Shokri-Mashhadi N. The effect of lutein and Zeaxanthine on dyslipidemia: A meta-analysis study. *Prostaglandins Other Lipid Mediat.* 2023 Feb;164:106691.
67. Long H, Huang R, Zhu S, Wang Z, Liu X, Zhu Z. Polysaccharide from *Caulerpa lentillifera* alleviates hyperlipidaemia through altering bile acid metabolism mediated by gut microbiota. *Int J Biol Macromol.* 2025 May;306:141663.
68. Baravia PA, Qhabibi FR, Hadinata E, Helda Katuuk SH, Alfaray RI, Rampengan DDCH, et al. Algal peptides for future food: Key players and multifaceted agents in the fight against cardiometabolic syndrome. *J Agric Food Res.* 2025 Apr;20:101786.
69. Cani PD, de Vos WM. Next-Generation Beneficial Microbes: The Case of *Akkermansia muciniphila*. *Front Microbiol.* 2017;8.
70. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits. *Cell.* 2014;156(1–2):84–96.

71. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. *Front Endocrinol (Lausanne)*. 2023;14.
72. Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. *Nat Rev Immunol*. 2019;20(1):40–54.
73. Petakh P, Kamyshna I, Kamyshnyi A. Effects of metformin on the gut microbiota: A systematic review. *Mol Metab*. 2023;77:101805.
74. Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science* (1979). 2018;359(6380):1151–6.
75. Du J, Xiao M, Sudo N, Liu Q. Bioactive peptides of marine organisms: Roles in the reduction and control of cardiovascular diseases. *Food Sci Nutr*. 2024 Aug 23;12(8):5271–84.
76. Hamadou M. Bioactive peptides and metabolic health: a mechanistic review of the impact on insulin sensitivity, lipid profiles, and inflammation. *Applied Food Research*. 2025 Dec;5(2):101056.
77. Bao X, Wu J. Impact of food-derived bioactive peptides on gut function and health. *Food Research International*. 2021 Sep;147:110485.
78. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? *Clinical Nutrition*. 1999;18(6):353–8.
79. Feingold KR. Introduction to Lipids and Lipoproteins. 2000.
80. Rybak M, Wojdyło A. Inhibition of α -Amylase, α -Glucosidase, Pancreatic Lipase, 15-Lipoxygenase and Acetylcholinesterase Modulated by Polyphenolic Compounds, Organic Acids, and Carbohydrates of *Prunus domestica* Fruit. *Antioxidants*. 2023 Jul 3;12(7):1380.
81. Shahidi F, Saeid A. Bioactivity of Marine-Derived Peptides and Proteins: A Review. *Mar Drugs*. 2025 Apr 4;23(4):157.
82. Kotake-Nara E, Yonekura L, Nagao A. Effect of Glycerophospholipid Class on the β -Carotene Uptake by Human Intestinal Caco-2 Cells. *Biosci Biotechnol Biochem*. 2010 Jan 23;74(1):209–11.
83. Rabiei S. Marine-Derived Bioactive Peptides with Pharmacological Activities- A Review. *Journal of Clinical and Diagnosis. Research*. 2017;
84. Lehrke M, Lazar MA. The Many Faces of PPAR γ . *Cell*. 2005;123(6):993–9.
85. Jeninga EH, Gurnell M, Kalkhoven E. Functional implications of genetic variation in human PPAR γ . *Trends in Endocrinology & Metabolism*. 2009;20(8):380–7.
86. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol*. 2011;11(2):85–97.
87. Kim MB, Lee J, Lee JY. Targeting Mitochondrial Dysfunction for the Prevention and Treatment of Metabolic Disease by Bioactive Food Components. *J Lipid Atheroscler*. 2024;13(3):306.

88. Ding L, Luo X, Wen W. Fucoxanthin-Loaded Solid Lipid Nanoparticles Exert Potent Therapeutic Efficacy in Combating High-Fat Diet Induced Obesity in Mice. *Int J Mol Sci*. 2025;26(11):5249.
89. Manabe Y, Sugawara T. Potential of siphonaxanthin, a green algal carotenoid, to prevent obesity and related diseases. *J Nat Med*. 2025 Apr 12;
90. Abu Shelbayeh O, Arroum T, Morris S, Busch KB. PGC-1 α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response. *Antioxidants*. 2023 May 10;12(5):1075.
91. Dominy JE, Puigserver P. Mitochondrial Biogenesis through Activation of Nuclear Signaling Proteins. *Cold Spring Harb Perspect Biol* [Internet]. 2013;5(7):a015008–a015008. Available from: <http://dx.doi.org/10.1101/cshperspect.a015008>
92. Wu MT, Chou HN, Huang C jang. Dietary Fucoxanthin Increases Metabolic Rate and Upregulated mRNA Expressions of the PGC-1 α Network, Mitochondrial Biogenesis and Fusion Genes in White Adipose Tissues of Mice. *Mar Drugs*. 2014;12(2):964–82.
93. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. *Nat Rev Mol Cell Biol*. 2006;7(2):85–96.
94. Zhang Y, Xu W, Huang X, Zhao Y, Ren Q, Hong Z, et al. Fucoxanthin ameliorates hyperglycemia, hyperlipidemia and insulin resistance in diabetic mice partially through IRS-1/PI3K/Akt and AMPK pathways. *J Funct Foods*. 2018;48:515–24.
95. Chambers ES, Preston T, Frost G, Morrison DJ. Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health. *Curr Nutr Rep*. 2018;7(4):198–206.
96. Kim B, Choi HN, Yim JE. Effect of Diet on the Gut Microbiota Associated with Obesity. *Journal of Obesity & Metabolic Syndrome*. 2019;28(4):216–24.
97. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013 Aug 29;500(7464):541–6.
98. Miquel S, Martín R, Rossi O, Bermúdez-Humarán L, Chatel J, Sokol H, et al. Faecalibacterium prausnitzii and human intestinal health. *Curr Opin Microbiol*. 2013 Jun;16(3):255–61.
99. O’Callaghan A, van Sinderen D. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. *Front Microbiol*. 2016 Jun 15;7.
100. Yang J, Li Y, Wen Z, Liu W, Meng L, Huang H. Oscillospira - a candidate for the next-generation probiotics. *Gut Microbes*. 2021;13(1).
101. Hall AB, Yassour M, Sauk J, Garner A, Jiang X, Arthur T, et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. *Genome Med*. 2017 Dec 28;9(1):103.
102. Reboul E. Absorption of Vitamin A and Carotenoids by the Enterocyte: Focus on Transport Proteins. *Nutrients*. 2013 Sep 12;5(9):3563–81.
103. Mayulu H, Daru TP, Tricahyadinata I. In vitro evaluation of ruminal digestibility and fermentation characteristics of local feedstuff-based beef cattle ration. *Res*. 2023 Jun 28;11:834.

104. Miquel S, Martín R, Rossi O, Bermúdez-Humarán L, Chatel J, Sokol H, et al. Faecalibacterium prausnitzii and human intestinal health. *Curr Opin Microbiol*. 2013 Jun;16(3):255–61.
105. Hu W, Gao W, Liu Z, Fang Z, Wang H, Zhao J, et al. Specific Strains of Faecalibacterium prausnitzii Ameliorate Nonalcoholic Fatty Liver Disease in Mice in Association with Gut Microbiota Regulation. *Nutrients*. 2022 Jul 19;14(14):2945.
106. Aoki R, Kamikado K, Suda W, Takii H, Mikami Y, Suganuma N, et al. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. *Sci Rep*. 2017 Mar 2;7(1):43522.
107. Sasaki K, Sasaki D, Sasaki K, Nishidono Y, Yamamori A, Tanaka K, et al. Growth stimulation of Bifidobacterium from human colon using daikenchuto in an in vitro model of human intestinal microbiota. *Sci Rep*. 2021 Feb 25;11(1):4580.
108. Yang J, Li Y, Wen Z, Liu W, Meng L, Huang H. Oscillospira - a candidate for the next-generation probiotics. *Gut Microbes*. 2021;13(1).
109. Parsaei M, Sarafriz N, Moaddab SY, Ebrahimzadeh Leylabadlo H. The importance of Faecalibacterium prausnitzii in human health and diseases. *New Microbes New Infect*. 2021;43:100928.
110. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut*. 2015;65(3):426–36.
111. Gao F, Cheng C, Li R, Chen Z, Tang K, Du G. The role of Akkermansia muciniphila in maintaining health: a bibliometric study. *Front Med (Lausanne)*. 2025;12.
112. Chulenbayeva L, Issilbayeva A, Sailybayeva A, Bekbossynova M, Kozhakhmetov S, Kushugulova A. Short-Chain Fatty Acids and Their Metabolic Interactions in Heart Failure. *Biomedicines*. 2025;13(2):343.
113. Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. *Nat Rev Endocrinol*. 2019;15(5):261–73.
114. van der Beek CM, Canfora EE, Lenaerts K, Troost FJ, Olde Damink SWM, Holst JJ, et al. Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men. *Clin Sci*. 2016;130(22):2073–82.
115. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance. *JAMA*. 2003;290(4):486.
116. Maeda H, Kanno S, Kodate M, Hosokawa M, Miyashita K. Fucoxanthinol, Metabolite of Fucoxanthin, Improves Obesity-Induced Inflammation in Adipocyte Cells. *Mar Drugs*. 2015;13(8):4799–813.

117. Zhang Y, Xu W, Huang X, Zhao Y, Ren Q, Hong Z, et al. Fucoxanthin ameliorates hyperglycemia, hyperlipidemia and insulin resistance in diabetic mice partially through IRS-1/PI3K/Akt and AMPK pathways. *J Funct Foods*. 2018;48:515–24.
118. Zaky AA, Simal-Gandara J, Eun JB, Shim JH, Abd El-Aty AM. Bioactivities, Applications, Safety, and Health Benefits of Bioactive Peptides From Food and By-Products: A Review. *Front Nutr*. 2022 Jan 20;8.
119. Shoelson SE, Herrero L, Naaz A. Obesity, Inflammation, and Insulin Resistance. *Gastroenterology*. 2007 May;132(6):2169–80.
120. Donath X, Saint-Martin C, Dubois-Laforgue D, Rajasingham R, Mifsud F, Ciangura C, et al. Next-generation sequencing identifies monogenic diabetes in 16% of patients with late adolescence/adult-onset diabetes selected on a clinical basis: a cross-sectional analysis. *BMC Med*. 2019 Dec 11;17(1):132.
121. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. *Gut*. 2014 Sep;63(9):1513–21.
122. Zhou Y, Zhang J, Xu K, Zhang W, Chen F, Liu B, et al. Fucoxanthin improves serum lipids, liver metabolism and gut microbiota in hyperlipidemia mice. *Food Science and Human Wellness*. 2025;14(1):9250017.
123. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. 2013 Dec 13;504(7480):451–5.
124. Ellison SL. Carotenoids: Physiology. In: Encyclopedia of Food and Health. *Elsevier*; 2016. p. 670–5.
125. Naveen J, Baskaran V. Antidiabetic plant-derived nutraceuticals: a critical review. *Eur J Nutr*. 2018 Jun 11;57(4):1275–99.
126. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2009;5(3):150–9.
127. Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? *J Nutr Biochem*. 2019 Jan;63:101–8.